Mathy, R. M.
Kuhn, T. C.
Kappes, J.
Wielpütz, M. O.
Ruhparwar, A.
Frankenstein, L.
Tanner, M.
Geis, N.
Fischer, C.
Kasperk, C.
Heussel, C. P.
Kreuter, M.
Wilkens, F. M.
Article History
Received: 13 January 2019
Revised: 8 July 2019
Accepted: 10 August 2019
First Online: 30 June 2020
Compliance with ethical guidelines
:
: M.O. Wielpütz reports grants from Vertex, grants from Boehringer Ingelheim and grants from Christiane Herzog Stiftung e. V. outside the submitted work. N. Geis received speaker’s honoraria from W.L. Gore & Associates GmbH and Daiichi Sankyo Deutschland GmbH outside the submitted work. C.P. Heussel received lecture fees from Novartis, Basilea and Bayer and research funding from the German Center for Lung Research outside the submitted work. Stock ownership in medical industry: GSK. R.M. Mathy, T.C. Kuhn, J. Kappes, A. Ruhparwar, L. Frankenstein, M. Tanner, C. Fischer, C. Kasperk, M. Kreuter and F.M. Wilkens declare that they have no competing interests.
: For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case. Additional written informed consent was obtained from all individual participants or their legal representatives for whom identifying information is included in this article.